StonvexLoading…
StonvexStonvexStonvexCore line items from RXRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $6.47M | $74.68M | $39.14M | $33.97M |
Operating Income | $-128.50M | $-648.13M | $-539.80M | $-367.60M |
Net Income | $-117.50M | $-644.76M | $-536.64M | $-374.38M |
EPS (Diluted) | $-0.22 | $-1.44 | $-1.27 | $-0.91 |
Total Assets | $1.34B | $1.47B | $1.40B | $1.30B |
Total Liabilities | $314.75M | $343.26M | $352.58M | $383.21M |
Cash & Equivalents | $654.47M | $743.29M | $659.84M | $525.11M |
Free Cash Flow OCF − CapEx | $-81.36M | $-378.28M | $-330.96M | $-213.36M |
Shares Outstanding | 530.63M | 528.18M | 491.80M | 432.83M |